Avid Bioservices, Inc.

Good day, ladies and gentlemen, and welcome to the AVID Bioservices fourth quarter and fiscal year end 2022 financial results conference call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will follow at that time. As a reminder, this conference call may be recorded. I would now like to hand the conference over to Tim Bronze of AVID's Investor Relations Group. Please go ahead.

Thank you. Good afternoon and thank you for joining us. On today's call, we have Nick Green, President and CEO, Dan Hart, Chief Financial Officer, and Matt Quitniak, App Chief Commercial Officer. Today, we will be providing an overview of Abbott Bioservices' contract development and manufacturing business, including updates on corporate activities and financial results for the quarter and year ended April 30th, 2022. After our prepared remarks, we will welcome your questions. Before we begin, I'd like to caution that comments made during this conference call today, June 29, 2022, will contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 concerning the current belief of the company, which involves a number of assumptions, risks, and uncertainties. Actual results could differ from these statements, and the company undertakes no obligation to revise or update any statement made today. I encourage you to review all of the company's filings with the Securities and Exchange Commission concerning these and other matters. Our earnings press release and this call will include discussion of certain non-GAAP information. You can find our earnings press release, including relevant non-GAAP reconciliations, on our corporate website at avidbio.com. With that, I will turn the call over to Nick Green, AVID's President and CEO.

Thank you, Tim, and thank you to everyone who has dialed in and to those who are participating via webcast. Fiscal 22 was an exceptionally strong year for AVID. In every measure, including financial, business development, and operations, we exceeded our stated goals for the year and extended the growth trajectory established in Fiscal 21. Revenues for Fiscal 22 reflected impressive year-over-year growth. and a doubling of the revenues as compared to our fiscal year 20. Our business development team signed multiple new orders, resulting in the company ending the fiscal year with its highest backlog to date. Operationally, we continue to make progress on the ongoing expansions, recently opening our new cell and gene therapy analytical and process development laboratories exactly eight months to the day that we announced our intention to expand into this business. This is the second expansion we have brought online this calendar year. Matt and I will provide additional details on business development and operations for the period following an overview of our fourth quarter and fiscal financial year 2022 financial results. And for that, I'll turn the call over to Dan.